372 related articles for article (PubMed ID: 28814858)
21. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP; Martinez FJ; Rodriguez-Roisin R; Fogarty C; Gotfried M; Denenberg M; Gottschlich G; Donohue JF; Orevillo C; Darken P; St Rose E; Strom S; Fischer T; Golden M; Reisner C
Respir Med; 2016 Nov; 120():16-24. PubMed ID: 27817811
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
[TBL] [Abstract][Full Text] [Related]
25. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
26. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
28. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
Babu KS; Morjaria JB
Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
[TBL] [Abstract][Full Text] [Related]
29. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Usmani O; Roche N; Wahab E; Israel S; Jenkins M; Trivedi R; Dorinsky P; Aurivillius M
Respir Res; 2021 Oct; 22(1):261. PubMed ID: 34620167
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
32. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
[TBL] [Abstract][Full Text] [Related]
33. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
34. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
Haley R; Gupta N; Sethi S
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
[No Abstract] [Full Text] [Related]
35. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Ficker JH; Rabe KF; Welte T
Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
[TBL] [Abstract][Full Text] [Related]
36. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Aurivillius M; Reisner C; Dorinsky P;
N Engl J Med; 2020 Jul; 383(1):35-48. PubMed ID: 32579807
[TBL] [Abstract][Full Text] [Related]
37. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
38. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
40. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
